Elana Thieme and Mark Mendoza, fourth-year graduate students in the Molecular and Cell Biology (MCB) PhD Program jointly ...

A new international study has delivered a rare dose of good news in the fight against aggressive brain tumors. Researchers ...

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden ...

In 2025, UC Davis once again proved why it stands among the world’s leading research universities — not only by pushing ...

The FDA's fast track designation acknowledges the combination's promising early efficacy and safety profile in treating MSS mCRC. Early data from a phase 1b/2 study showed deep, durable responses with ...

Bristol Myers Squibb (NYSE: BMY) reinforces its hematology leadership through new research across multiple therapies for patients with lymphoma at the 67th American Society of Hematology (ASH) Annual ...

ORLANDO -- A gene therapy that could transform CAR T-cell treatment achieved rapid and potentially durable measurable ...

BeyondSpring's shares rallied ahead of the opening bell after the biopharmaceutical company reported positive results among an Asian subset in a late-stage trial of its lung cancer treatment. In ...

YourStory presents the daily news roundup from the Indian startup ecosystem and beyond. Here’s the roundup for Wednesday, ...

Qihan's QT-019B program is supported by IND clearance for rSLE from both the US FDA and the China NMPA. The FDA has also granted Fast Track Designation for the SLE-ITP indication. Phase 1 enrollment ...

GTA182 demonstrates favorable safety, dose-proportional pharmacokinetics, robust PRMT5 pathway inhibition, and encouraging ...

New Investigator Sponsored Data Suggest Trilaciclib May Mitigate Chemotherapy-Induced TP53-Mutant Clonal Hematopoiesis. EINPresswire/ -- Pharmacosmos Therapeutics Inc. today announced the presentation ...